Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
State of the Art: Cardiothoracic Tumors
share announcement

State of the Art: Cardiothoracic Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 25 July 2025 | Viewed by 3157

Special Issue Editors

Prof. Dr. Calvin Sze Hang Ng

E-Mail Website
Guest Editor
Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
Interests: ablation; hybrid theatre; image-guided surgery; interventional bronchoscopy; lung cancer; minimally invasive surgery; navigation bronchoscopy; robotic bronchoscopy; video-assisted thoracic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Panagiotis Tasoudis

E-Mail Website
Guest Editor
Department of Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Interests: non-small cell lung cancer; robotic-assisted surgery; immunotherapy

Special Issue Information

Dear Colleagues,

We are delighted to announce a Special Issue of Cancers titled "State of the Art: Cardiothoracic Tumors" which aims to capture the latest advancements and research developments in the diagnosis, treatment, and management of cardiothoracic tumors. These malignancies pose significant clinical challenges due to their complex nature and critical location, necessitating continuous updates and dissemination of knowledge in this rapidly evolving field.

This Special Issue will cover a broad range of topics including innovative diagnostic imaging techniques, cutting-edge surgical methods, novel findings regarding immunotherapy, chemotherapy, and radiotherapy approaches, and the latest findings in molecular and genetic research. By bringing together contributions from leading experts, we aim to provide a comprehensive overview of the current state of the art in cardiothoracic oncology and highlight future directions for research and clinical practice.

We invite researchers and clinicians to submit original research articles, review papers, case studies, and clinical trial reports that explore these themes. Your contributions will be instrumental in advancing our understanding and treatment of cardiothoracic tumors.

Prof. Dr. Calvin Sze Hang Ng
Dr. Panagiotis Tasoudis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • non-small cell lung cancer
  • esophageal cancer
  • diagnostic imaging
  • robotic-assisted thoracoscopic surgery
  • video-assisted thoracoscopic surgery
  • immunotherapy
  • radiotherapy
  • molecular oncology
  • lung cancer screening

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2767 KiB  
Article
Initial Experience of Single-Port Robotic Lobectomy for Large-Sized Non-Small Cell Lung Cancer: A Single-Center Retrospective Study
by Jun Hee Lee, Byung Mo Gu, Hwan Seok Yong, Soon Young Hwang and Hyun Koo Kim
Cancers 2024, 16(17), 3091; https://doi.org/10.3390/cancers16173091 - 5 Sep 2024
Viewed by 683
Abstract
Single-port robotic-assisted thoracic surgery (SP-RATS) lobectomy using the da Vinci Xi system has been performed by several pioneers. However, due to the severe collisions and the steep learning curve, this approach is not yet widely used. This study aimed to evaluate the feasibility [...] Read more.
Single-port robotic-assisted thoracic surgery (SP-RATS) lobectomy using the da Vinci Xi system has been performed by several pioneers. However, due to the severe collisions and the steep learning curve, this approach is not yet widely used. This study aimed to evaluate the feasibility of SP-RATS lobectomy for large-sized non-small cell lung cancer (NSCLC). As we believe that for large-sized tumors it is reasonable to make a slightly larger incision, we performed SP-RATS lobectomy for large-sized NSCLC (greater than 5 cm) through a single incision (6–8 cm). Eleven patients underwent SP-RATS lobectomy using the da Vinci Xi system at our institution from April 2022 to May 2024. The median tumor size on computed tomography and on pathology was 6.6 cm [interquartile range (IQR), 6.1–7.5 cm] and 6 cm [IQR, 5.1–7.1], respectively. The median total operative time was 198 min [IQR, 159–260 min], and the median postoperative length of stay was 4 days [IQR, 4–10 days], with no major postoperative complications (≥grade III on the Clavien–Dindo classification). Our approach may combine the benefits of single-port surgery with those of robotic surgery and is safe, feasible, and may promote better outcomes in patients with large-sized NSCLC. Full article
(This article belongs to the Special Issue State of the Art: Cardiothoracic Tumors)
►▼ Show Figures

Graphical abstract

15 pages, 2407 KiB  
Article
Subxiphoid Single-Port Robotic Thymectomy Using the Single-Port Robotic System versus VATS: A Multi-Institutional, Retrospective, and Propensity Score-Matched Study
by Jun Hee Lee, Jinwook Hwang, Tae Hyun Park, Byung Mo Gu, Younggi Jung, Eunjue Yi, Sungho Lee, Soon Young Hwang, Jae ho Chung and Hyun Koo Kim
Cancers 2024, 16(16), 2856; https://doi.org/10.3390/cancers16162856 - 15 Aug 2024
Viewed by 1172
Abstract
Subxiphoid thymectomy is a novel alternative to the transthoracic approach and sternotomy, with potential benefits, such as reduced postoperative pain and faster recovery. We previously reported the initial experience with subxiphoid single-port robotic-assisted thoracic surgery (SRATS) thymectomy using the single-port robotic system (SPS). [...] Read more.
Subxiphoid thymectomy is a novel alternative to the transthoracic approach and sternotomy, with potential benefits, such as reduced postoperative pain and faster recovery. We previously reported the initial experience with subxiphoid single-port robotic-assisted thoracic surgery (SRATS) thymectomy using the single-port robotic system (SPS). However, the efficacy of this technique remains unknown. Thus, this study examined the multi-institutional experience with SRATS thymectomy and compared the perioperative outcomes of this technique to those of subxiphoid single-port video-assisted thoracic surgery (SVATS) thymectomy. The data of patients who underwent subxiphoid SRATS and SVATS thymectomy, performed by three thoracic surgeons at three institutions between September 2018 and May 2024, were retrospectively collected. In total, 110 patients were included, with 85 and 25 undergoing SRATS and SVATS thymectomy, respectively. After propensity score matching, 25 patients were included in each group. The SRATS group was associated with a lower conversion rate to multi-port surgery (0% vs. 20%, p = 0.05), shorter chest tube drainage duration (1.32 ± 0.75 vs. 2.00 ± 1.29 days, p = 0.003), and a shorter postoperative hospital stay (2.52 ± 1.00 vs. 5.08 ± 5.20 days, p = 0.003). Subxiphoid SRATS thymectomy using the SPS is feasible and is a good alternative to conventional thymectomy. Further studies are necessary to confirm its benefits. Full article
(This article belongs to the Special Issue State of the Art: Cardiothoracic Tumors)
►▼ Show Figures

Graphical abstract

9 pages, 525 KiB  
Article
The Role of Immunotherapy in the Management of Esophageal Cancer in Patients Treated with Neoadjuvant Chemoradiation: An Analysis of the National Cancer Database
by Panagiotis Tasoudis, Vasiliki Manaki, Yoshiko Iwai, Steven A. Buckeridge, Audrey L. Khoury, Chris B. Agala, Benjamin E. Haithcock, Gita N. Mody and Jason M. Long
Cancers 2024, 16(13), 2460; https://doi.org/10.3390/cancers16132460 - 4 Jul 2024
Cited by 1 | Viewed by 946
Abstract
Background: The current National Comprehensive Cancer Network advises neoadjuvant chemoradiotherapy followed by surgery for locally advanced cases of esophageal cancer. The role of immunotherapy in this context is under heavy investigation. Methods: Patients with esophageal adenocarcinoma were identified in the National Cancer Database [...] Read more.
Background: The current National Comprehensive Cancer Network advises neoadjuvant chemoradiotherapy followed by surgery for locally advanced cases of esophageal cancer. The role of immunotherapy in this context is under heavy investigation. Methods: Patients with esophageal adenocarcinoma were identified in the National Cancer Database (NCDB) from 2004 to 2019. Three groups were generated as follows: (a) no immunotherapy, (b) neoadjuvant immunotherapy, and (c) adjuvant immunotherapy. Overall survival was evaluated using the Kaplan–Meier method and Cox proportional hazard analysis, adjusting for previously described risk factors for mortality. Results: Of the total 14,244 patients diagnosed with esophageal adenocarcinoma who received neoadjuvant chemoradiation, 14,065 patients did not receive immunotherapy, 110 received neoadjuvant immunotherapy, and 69 received adjuvant immunotherapy. When adjusting for established risk factors, adjuvant immunotherapy was associated with significantly improved survival compared to no immunotherapy and neoadjuvant immunotherapy during a median follow-up period of 35.2 months. No difference was noted among patients who received no immunotherapy vs. neoadjuvant immunotherapy in the same model. Conclusions: In this retrospective analysis of the NCDB, receiving adjuvant immunotherapy offered a significant survival advantage compared to no immunotherapy and neoadjuvant immunotherapy in the treatment of esophageal adenocarcinoma. The addition of neoadjuvant immunotherapy to patients treated with neoadjuvant chemoradiation did not improve survival in this cohort. Further studies are warranted to investigate the long-term outcomes of immunotherapy in esophageal cancer. Full article
(This article belongs to the Special Issue State of the Art: Cardiothoracic Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop